Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
US10328145B2 · kind B2 · utility
0Cited by
6References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2016 |
| Grant date | Jun 25, 2019 |
| Priority date | — |
| Expiry date | Mar 25, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/01064
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.